Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope

(Image Credit: AdobeStock/Sergey)

Norlase, a leading global ophthalmic laser manufacturer, announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for Norlase LYNX. LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.

The laser and pattern module allows surgeons to treat patients virtually anywhere, built into an ergonomic headset, eliminating the need for an external laser source. With LYNX, surgeons can also move freely and efficiently during treatment by using advanced features, such as an intuitive wireless user interface and multilingual voice control.¹

“The most important resource for today’s ophthalmologists is time,” Oliver Hvidt, CEO and co-founder of Norlase, said. “That’s why they’ve been asking for pattern LIO ever since the invention of pattern lasers more than 15 years ago. With LYNX, pattern LIO is finally here. Faster LIO treatments means less ergonomic stress, more quality time with patients and more practice days that end on time. I’m extremely proud of our team and thankful to the doctors who helped guide the development. LYNX is our fourth product launch in just five years and a testament to our ongoing mission to simplify ophthalmic practice, while maximizing efficiency and comfort.”

LYNX also features battery-powered portability and treatment flexibility, a full pattern palette and simplyCLEAR safety filters for enhanced visualization.¹

Since its release, early users of LYNX have shared positive results of the pattern scanning LIO. Daniel Diaz, Retina Consultants of Miami, said, “This innovative device combines the speed and efficiency of pattern laser technology with unmatched portability and comfort, setting a new standard for indirect laser treatments. The device’s portability and robust laser pattern options make it a cutting-edge tool that has significantly improved the pace and quality of my retina treatments.”

LYNX is Norlase’s fourth product announcement since 2019, with the new product promising to make cutting-edge laser technology more accessible to ophthalmologists globally.¹

Reference:

1. Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Opthalmoscope. Norlase. Accessed January 27, 2025. Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX™ Pattern Scanning Laser Indirect Ophthalmoscope | Norlase